地夫可特国内能买到吗？在哪能买到？

Introduction: Deflazacort has not yet been officially launched in China. The original drug is produced by the Spanish company Fare.S.A. There are already generic versions of the drug in the United States, Germany and India. The domestic purchase channels and drug interactions of deflazacort are the focus of attention of patients or medical staff.

Is deflazacort available in China

Currently it has not been officially launched in China. Patients cannot purchase it directly in China and may need to purchase it through other legal channels.

Marketing situation

Deflazacort has not yet been approved and officially launched in China, and domestic patients cannot directly purchase the drug.

Market Feedback

Deflazacort has shown good efficacy and safety in clinical applications and has been widely recognized by doctors and patients. Most patients are satisfied with its treatment effects.

Where can I buy deflazacort?

The purchasing channels for deflazacort are diversified. Patients can choose the appropriate purchasing method according to their own needs and conditions. The following are several common purchasing channels.

Hospital Pharmacy

In countries where deflazacort is listed, such as the United States, many large local hospitals have specialized pharmacies. Patients can purchase deflazacort directly at the hospital pharmacy after treatment. This method ensures a reliable source of drugs, reduces intermediate links, and is suitable for patients who need immediate medication.

Physical pharmacies

Deflazacort is usually sold in local pharmacies in countries where deflazacort is listed, and patients can purchase it after presenting a medical prescription.

Medical service institutions

Domestic patients can help purchase deflazacort through medical service institutions. They can usually help purchase the original or generic version of deflazacort, and they can obtain the drug through direct mail.

Deflazacort drug interactions

Deflazacort may interact with other drugs, affecting drug efficacy or increasing the risk of adverse reactions. Patients should pay special attention to the following when using deflazacort.

Moderate or strong CYP3A4 inhibitor

Deflazacort’s active metabolite 21-desDFZ is a CYP3A4 substrate, and coadministration of deflazacort with clarithromycin (a strong CYP3A4 inhibitor) increases the total exposure to 21-desDFZ by approximately 3-fold. When a moderate or strong CYP3A4 inhibitor is used concurrently with deflazacort, give one-third of the recommended dose of deflazacort.

Moderate or strong CYP3A4 inducers

Coadministration of deflazacort with rifampicin significantly reduces 21-desDFZ exposure. Avoid concurrent use of strong (e.g., efavirenz) or moderate (e.g., carbamazepine, phenytoin) CYP3A4 inducers with deflazacort and Clinical Pharmacology.

By understanding the drug interactions of deflazacort, patients can better manage the medication process and reduce potential risks.